Darbepoetin alfa
- Generic Name
- Darbepoetin alfa
- Brand Names
- Aranesp
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 209810-58-2
- Unique Ingredient Identifier
- 15UQ94PT4P
- Background
Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
- Indication
For the treatment of anemia (from renal transplants or certain HIV treatment)
- Associated Conditions
- Anemia
- Associated Therapies
- -
Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-01-21
- Last Posted Date
- 2013-02-12
- Lead Sponsor
- Affymax
- Target Recruit Count
- 493
- Registration Number
- NCT00598442
- Locations
- 🇬🇧
Research Facility, London, United Kingdom
Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-01-21
- Last Posted Date
- 2013-02-12
- Lead Sponsor
- Affymax
- Target Recruit Count
- 490
- Registration Number
- NCT00598273
- Locations
- 🇵🇷
Research Facility, San Juan, Puerto Rico
Study of Erythropoietin to Treat Anemia Complicating Chronic Obstructive Pulmonary Disease
Phase 3
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2007-12-21
- Last Posted Date
- 2013-10-30
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Registration Number
- NCT00579046
- Locations
- 🇫🇷
CHU Henri Mondor, Creteil, France
Study of the Efficacy of Darbepoetin Alfa in the Treatment of Renal Anemia
Not Applicable
Completed
- Conditions
- First Posted Date
- 2007-11-26
- Last Posted Date
- 2011-06-16
- Lead Sponsor
- Hospital Authority, Hong Kong
- Target Recruit Count
- 16
- Registration Number
- NCT00563446
- Locations
- 🇨🇳
Princess Margaret Hospital, Hong Kong, China
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-11-16
- Last Posted Date
- 2016-11-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 307
- Registration Number
- NCT00559273
Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin Alfa
- First Posted Date
- 2007-10-08
- Last Posted Date
- 2013-04-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 300
- Registration Number
- NCT00540696
An Exploratory Sub-study for the RED-HF™ (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2007-09-24
- Last Posted Date
- 2011-04-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 12
- Registration Number
- NCT00534456
NESP Pediatric Study
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2013-05-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 120
- Registration Number
- NCT00527137
Phase 2 Study of Darbepoetin Alfa Extended Dosing
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2009-05-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 98
- Registration Number
- NCT00527215
Fixed Dose NESP Study in Subjects With CRI
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2009-05-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 75
- Registration Number
- NCT00526929
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath